Courses

← vista completa

Published on October 1, 2006 | http://doi.org/10.5867/medwave.2006.09.3388

P-glycoprotein as a prognostic factor and therapeutic target in patients with acute myeloid leukemia

Glicoproteína P como factor pronóstico y objetivo terapéutico en pacientes con leucemia mieloide aguda

Álvaro Pizarro Quevedo

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Álvaro Pizarro Quevedo

Hospital del Salvador
Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Pizarro Quevedo A. P-glycoprotein as a prognostic factor and therapeutic target in patients with acute myeloid leukemia. Medwave 2006;6(09):e3388 doi: 10.5867/medwave.2006.09.3388

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/10/2006

Index

Metrics

Not available at the moment.

Notes

References

  1. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP-1: Recent advances in the discovery of reversal agents. Med Res Rev. 2005 Jul;25(4):453-72. | CrossRef | PubMed
  2. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388-93. | CrossRef | PubMed
  3. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999 Dec 6;1461(2):237-62. | CrossRef | PubMed
  4. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001 Sep 1;98(5):1302-11. | CrossRef | PubMed
  5. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May 1;89(9):3323-9. | PubMed
  6. Wuchter C, Leonid K, Ruppert V, Schrappe M, Büchner T, Schoch C, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Haematologica. 2000 Jul;85(7):711-21. | PubMed
  7. Löwenberg B, Downing JR, Burnett A. Acute Myeloid leukemia. N Engl J Med. 1999 Sep 30;341(14):1051-62. | CrossRef | PubMed
  8. Baer M, Stephen G, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previouslyuntreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15;100(4):1224-32. | PubMed
  9. Boesch D, Gaveriaux C, Jachez B, Pourtier-ManzanedoA, Bollinger P, Loor F. In vivo circumventionof P-glycoprotein-mediated multidrug resistanceof tumor cells with SDZ PSC 833. Cancer Res. 1991 Aug 15;51(16):4226-33. | PubMed
  10. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol. 2000 May;18(9):1837-44. | PubMed
  11. Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, et al. Parallel phase 1 studies of daunorubicin given with cytosine arabinoside and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients _60 years of age with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol. 1999 Sep;17(9):2831-9. | PubMed
  12. van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood. 2005 Oct 15;106(8):2646-54. | CrossRef | PubMed
  13. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May 1;89(9):3323-9. | PubMed